ArticlePLoS neglected tropical diseases2013
Development of novel prime-boost strategies based on a tri-gene fusion recombinant L. tarentolae vaccine against experimental murine visceral leishmaniasis.
Article in PLoS neglected tropical diseases, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 73 citations in OpenAlex.
- Bulky pcDNA plasmid encoding Leishmania- and Sandfly-derived antigens resulted in transient Th1 response post Leishmania major infection in BALB/c mice.Scientific reports · 2026Article
- Advances inPathogens (Basel, Switzerland) · 2024Review
- Live attenuated-nonpathogenicFrontiers in microbiology · 2024Review
- Guidelines for the purification and characterization of extracellular vesicles of parasites.Journal of extracellular biology · 2023Article
- Leishmania tarentolae: a vaccine platform to target dendritic cells and a surrogate pathogen for next generation vaccine research in leishmaniases and viral infections.Parasites & vectors · 2023Review
- Leishmania tarentolae: A new frontier in the epidemiology and control of the leishmaniases.Transboundary and emerging diseases · 2022Review
- Vaccination in Leishmaniasis: A Review Article.Iranian biomedical journal · 2022Article
- Isolation, characterization, and functional study of extracellular vesicles derived fromFrontiers in cellular and infection microbiology · 2022Article
- Article
- Effect of transgenicIranian journal of basic medical sciences · 2021Article
- Leishmania tarentolae and Leishmania infantum in humans, dogs and cats in the Pelagie archipelago, southern Italy.PLoS neglected tropical diseases · 2021Article
- Article
- Review
- Leishmania tarentolae: Taxonomic classification and its application as a promising biotechnological expression host.PLoS neglected tropical diseases · 2019Review
- New Vaccine Formulations Containing a Modified Version of the Amastigote 2 Antigen and the Non-VirulentFrontiers in immunology · 2018Article
- Translating Observations From Leishmanization Into Non-Living Vaccines: The Potential of Dendritic Cell-Based Vaccination Strategies AgainstFrontiers in immunology · 2018Review
- Human Neutrophil Peptide 1 as immunotherapeutic agent against Leishmania infected BALB/c mice.PLoS neglected tropical diseases · 2017Article
- Arginase activity in pathogenic and non-pathogenic species of Leishmania parasites.PLoS neglected tropical diseases · 2017Article
- Alternative to Chemotherapy-The Unmet Demand against Leishmaniasis.Frontiers in immunology · 2017Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Visceral leishmaniasis (VL) is a vector-borne disease affecting humans and domestic animals that constitutes a serious public health problem in many countries. Although many antigens have been examined so far as protein- or DNA-based vaccines, none of them conferred complete long-term protection. The use of the lizard non-pathogenic to humans Leishmania (L.) tarentolae species as a live vaccine vector to deliver specific Leishmania antigens is a recent approach that needs to be explored further. In this study, we evaluated the effectiveness of live vaccination in protecting BALB/c mice against L. infantum infection using prime-boost regimens, namely Live/Live and DNA/Live. As a live vaccine, we used recombinant L. tarentolae expressing the L. donovani A2 antigen along with cysteine proteinases (CPA and CPB without its unusual C-terminal extension (CPB(-CTE))) as a tri-fusion gene. For DNA priming, the tri-fusion gene was encoded in pcDNA formulated with cationic solid lipid nanoparticles (cSLN) acting as an adjuvant. At different time points post-challenge, parasite burden and histopathological changes as well as humoral and cellular immune responses were assessed. Our results showed that immunization with both prime-boost A2-CPA-CPB(-CTE)-recombinant L. tarentolae protects BALB/c mice against L. infantum challenge. This protective immunity is associated with a Th1-type immune response due to high levels of IFN-γ production prior and after challenge and with lower levels of IL-10 production after challenge, leading to a significantly higher IFN-γ/IL-10 ratio compared to the control groups. Moreover, this immunization elicited high IgG1 and IgG2a humoral immune responses. Protection in mice was also correlated with a high nitric oxide production and low parasite burden. Altogether, these results indicate the promise of the A2-CPA-CPB(-CTE)-recombinant L. tarentolae as a safe live vaccine candidate against VL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.